Funding for this research was provided by:
Received: 11 June 2020
Accepted: 27 July 2020
First Online: 9 September 2020
Ethics approval and consent to participate
: The final protocols and informed consent forms were approved by the local ethics committee (e-Appendix InternalRef removed). The studies were performed in accordance with the Declaration of Helsinki, the International Council for Harmonisation/Good Clinical Practice guidelines, applicable regulatory requirements and the AstraZeneca policy on Bioethics. Volunteers provided voluntary, written informed consent before taking part in study procedures.
: Not applicable.
: VB was an employee of AstraZeneca at the time these studies were conducted and is now a current employee of IQVIA. LJ, UW-H, CA, BS, AL and IP are employees of AstraZeneca, and may own stock or stock options. AA was an employee of AstraZeneca at the time these studies were conducted and is now a current employee of Eloxx Pharmaceuticals. M-PM was a contractor to AstraZeneca at the time these studies were conducted. MA is an employee of PAREXEL. AstraZeneca provided funding to PAREXEL for the conduct of these studies.